移植骨髓间充质干细胞治疗胰腺炎的研究进展

Progress in treatment of pancreatitis with bone marrow mesenchymal stem cells

急性重症胰腺炎(severeacute pancreatitis,SAP)起病急,发病重,早期可致患者死亡,死亡率大约为20%-40%,急性胰腺炎主要是由胆石症和过度饮酒引起的,药物、毒素、感染、创伤、局部缺血、解剖异常、高钙血症、高脂血症、免疫疾病均可引起急性胰腺炎,但少见.尽管对于急性重症胰腺炎的诊治已经有了革命性的进步,但其死亡率仍较高.目前,对于急性重症胰腺炎的治疗方法多偏重于以抑制胰酶分泌、防止多个器官继发损害为主的原则,而对于胰腺本身功能恢复治疗的关注研究较少.因此,利用骨髓间充质干细胞(bone mesenchymal stem cells,BMSCs)对急性重症胰腺炎的研究有广泛的研究前景和较为重大的临床意义.

Severe acute pancreatitis, characterized by a rap- id onset and the heaviness of the disease, has a mortality rate of 20%-40%. The major causes of acute pancreatitis are symptomatic gallstone disease and excessive alcohol intake. Drugs, toxins, infections, trauma, ischemia, anatomic variants, hypercalcemia, hyperlipidemia and autoimmune disease are rare causes. Although revolutionary progress has been made in the diagnosis and treatment of severe acute pancreatitis, its mortality rate is still high. Currently, too much attention is paid to restraining pancreatic enzyme secretion and preventing multiple organ secondary damage in the treatment of severe acute pancreatitis, and promotion of functional recovery of the pancreas is less considered. Bone marrow mesenchymal stem cells can be used to promote the functional recovery of the pancreas in patients with severe acute pancreatitis.